DEF: MIRA Pharmaceuticals Sets Annual Meeting Date, Proposes Director Slate

MIRA Pharmaceuticals, Inc. has issued a proxy statement detailing its upcoming virtual Annual Meeting of Shareholders on September 11, 2026, where key proposals including director elections and auditor ratification will be addressed.

Summary

• MIRA Pharmaceuticals, Inc. is holding its Annual Meeting of Shareholders virtually on September 11, 2026, at 10:00 a.m. Eastern Time.
• Shareholders will vote on electing five directors, ratifying the appointment of Salberg & Company, P.A. as the independent auditor for fiscal year 2026, and approving the potential adjournment of the meeting.
• The record date for determining shareholders entitled to vote is July 21, 2026, with 42,022,087 shares of Common Stock outstanding.
• A quorum requires the presence of 33.33% of the Company's outstanding stock.
• The Board of Directors recommends voting FOR all proposals.
• The company has adopted a code of business conduct and ethics, an insider trading policy, and corporate governance guidelines.
• The Audit Committee has overseen the financial reporting process and recommended the inclusion of audited financial statements for fiscal year ended December 31, 2025.
• Shareholder proposals for the 2027 Annual Meeting must be received by March 30, 2027, for inclusion in proxy materials.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily focused on procedural matters for the annual shareholder meeting rather than significant operational or financial updates.

Positives

• The company is holding a virtual annual meeting to increase shareholder accessibility.
• Four of the five director nominees (Matthew Pratt Whalen, Dr. Matthew Del Giudice, Dr. Denil Shekhat, and Edward MacPherson) have been determined to be independent directors under Nasdaq Listing Rules.
• The Audit Committee has a financial expert (Matthew Whalen) as required by SEC rules.
• The company has a robust set of corporate governance documents including a code of conduct, insider trading policy, and corporate governance guidelines.
• All officers, directors, and greater than 10% owners timely filed their Section 16(a) reports for fiscal year 2025.
• The company has a clear process for shareholders to submit proposals and communicate with the Board.
• The company has a policy for reviewing and approving related party transactions, ensuring terms are comparable to arm's-length transactions.

Negatives

• Only 20% of the directors in office attended the company's 2025 annual meeting of shareholders.
• The Nominating and Corporate Governance Committee did not hold any meetings in fiscal year 2025.
• The company's hedging policy prohibits all employees, officers, and directors from trading in derivative securities related to its Common Stock and any transactions designed to hedge or offset a decrease in market value.
• The company has a history of related party transactions, including a significant line of credit and promissory note with Bay Shore Trust, which was paid off but involved a substantial warrant issuance.

Risks

• If a quorum is not present or sufficient votes are not received, the meeting may need to be adjourned to permit further solicitation of proxies.
• Broker non-votes will occur for the Director Election Proposal if beneficial owners do not provide voting instructions, as this is a non-routine matter.
• The company's insider trading policy strictly prohibits hedging activities, which could limit certain investment strategies for insiders.
• The company has a policy that prohibits loans to officers or loan guarantees to promoters.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It outlines proposals for the upcoming annual meeting, including the election of directors and ratification of the auditor for the fiscal year ending December 31, 2026.

Management Comments

• The Board recommends that shareholders vote FOR each of the Proposals.
• The company is making proxy materials available electronically via the Internet to provide greater access for shareholders.
• Promptly voting shares will save the company expenses and additional work of solicitation.
• The company believes that its terms obtained or consideration paid in related party transactions were comparable to terms available in arm's-length transactions with unrelated third parties.

Industry Context

StockSavvy.ai notes that MIRA Pharmaceuticals is following standard corporate governance practices by holding an annual shareholder meeting to elect directors and ratify auditors. The move to a virtual-only meeting is a trend seen across many companies to enhance accessibility and potentially reduce costs, though it can sometimes limit direct engagement compared to in-person events.

Management Changes

Corporate Governance

Related Party Transactions

• A line of credit and promissory note with Bay Shore Trust for up to $5,000,000 was entered into on April 28, 2023. A portion was converted to equity upon IPO, and the note was paid off as of December 31, 2023. A warrant for 1,000,000 shares was issued in consideration for the loan facility.
• The company has a policy for reviewing and approving related party transactions, requiring approval from independent directors for future transactions.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, impacting board composition and oversight. Their ability to attend and vote virtually is facilitated.
• Management and Employees: Subject to the code of conduct, insider trading policy, and compensation plans outlined.
• Auditors: Appointment of Salberg & Company, P.A. is subject to shareholder ratification.

Next Steps

• Shareholders to vote on director elections, auditor ratification, and adjournment proposal.
• Final voting results to be published in a Form 8-K within four business days after the Annual Meeting.
• Shareholder proposals for the 2027 Annual Meeting must be submitted by specified deadlines.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Director Election, Auditor Ratification, Corporate Governance, Shareholder Proposals, Virtual Meeting, MIRA Pharmaceuticals